COEXISTENCE OF POLYCYTHEMIA VERA AND MULTIPLE MYELOMA: A CASE REPORT
Abstract
Introduction: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by the clonal proliferation of erythroid, myeloid, and megakaryocytic lineages, most commonly associated with the JAK2 V617F mutation. Multiple myeloma (MM), on the other hand, is a malignant plasma cell neoplasm characterized by clonal proliferation of plasma cells in the bone marrow and the secretion of monoclonal immunoglobulin. The coexistence of PV and MM in the same patient is extremely rare, as these disorders originate from distinct hematopoietic lineages.
Case report: We report the case of a patient with long-standing PV who subsequently developed MM, highlighting the diagnostic and therapeutic challenges of this unusual association.
Conclusion: The prognosis of patients with concomitant hematologic malignancies depends on the type and aggressiveness of the diseases, the clinical stage at the time of detection, and the adequacy of the therapeutic approach. This case highlights the importance of avoiding automatic attribution of new clinical symptoms to a pre-existing diagnosis. A broad differential diagnosis should always be maintained, with each new symptom evaluated individually, allowing for early recognition of additional hematologic pathology and timely initiation of appropriate treatment.
References
Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023 Sep;98(9):1465-87. doi: 10.1002/ajh.27002.
Tremblay D, Kremyanskaya M, Mascarenhas J, Hoffman R. Diagnosis and Treatment of Polycythemia Vera: A Review. JAMA. 2025 Jan 14;333(2):153-60. doi: 10.1001/jama.2024.20377.
Lu X, Chang R. Polycythemia Vera. 2023 Apr 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557660/
Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC Cancer. 2019 Jun 17;19(1):590. doi: 10.1186/s12885-019-5764-4.
Patel AB, Masarova L, Mesa RA, Hobbs G, Pemmaraju N. Polycythemia vera: past, present and future. Leuk Lymphoma. 2024 Nov;65(11):1552-64. doi: 10.1080/10428194.2024.2361836.
Gay F, Marchetti E, Bertuglia G. Multiple Myeloma Unpacked. Hematol Oncol. 2025 Jun;43 Suppl 2(Suppl 2):e70067. doi: 10.1002/hon.70067.
Ho M, Paruzzo L, Minehart J, Nabar N, Noll JH, Luo T, et al. Extramedullary Multiple Myeloma: Challenges and Opportunities. Curr Oncol. 2025 Mar 20;32(3):182. doi: 10.3390/curroncol32030182.
Kimura H, Furukawa M, Mori H, Shiga Y, Asai J, Satoh K, et al. Development of multiple myeloma after 15 years of treatment for polycythemia vera and successful treatment using bortezomib: A case report. Clin Case Rep. 2022 Nov 19;10(11): e6614. doi: 10.1002/ccr3.6614.
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022 Feb 1;327(5):464-77. doi: 10.1001/jama.2022.0003.
Yuan J, Liu X, Wang Z, Li L, Wang F. Concurrent Polycythemia Vera with Newly Diagnosed Multiple Myeloma: Case Report and Literature Review. J Inflamm Res. 2023 Sep 18;16:4117-21. doi: 10.2147/JIR.S428977.
Landsman A, Barua P, Podrumar A. A Rare Coexistence of Multiple Myeloma and Polycythemia Vera. J Hematol. 2023 Oct;12(5):227-30. doi: 10.14740/jh1167.
Xiang Q, Chu B, Lu M, Shi L, Wang Y, Fang L, et al. Coexistence of myeloproliferative neoplasms with multiple myeloma. Cancer Pathog Ther. 2023 Dec 9;2(3):212-4. doi: 10.1016/j.cpt.2023.12.001.
Allegra A, Pioggia G, Tonacci A, Casciaro M, Musolino C, Gangemi S. Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR-ABL-Negative Myeloproliferative Neoplasm. Antioxidants (Basel). 2020 Oct 23;9(11):1037. doi: 10.3390/antiox9111037.
